PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings • Assumptions PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview of ADCs • Antibodies • Evolution of mAb therapeutics • Conjugated mAbs • History • Key components in ADCs • Next-generation ADCs • Advantages • Challenges • Outsourcing of ADCs manufacturing • Emergence of ADCs • Current marketed ADCs • PART 06: Pipeline portfolio • Information on pipeline candidates PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by MOA • IgG1 antibodies • HER2 antibodies PART 09: Market segmentation by technologies used in ADCs • Seattle Genetics (SGEN) technology • ImmunoGen (IMGN) technology • Immunomedics (IMMU) technology PART 10: Geographical segmentation PART 11: Market drivers • Robust late-stage pipeline • Rising prevalence of cancers • Increase in demand for antibody conjugates • Reimbursement policies PART 12: Impact of drivers PART 13: Market challenges • High developmental costs • Stringent regulations • Risk of side effects PART 14: Impact of drivers and challenges PART 15: Market trends • Strategic alliances • Increased outsourcing of drug development • Emergence of targeted and combination therapies PART 16: Vendor landscape • Competitive scenario • Key news • F. Hoffmann-La Roche • Seattle Genetics • Takeda Pharmaceuticals PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Comparison of small molecule and mAbs Exhibit 03: Preparation of mAbs Exhibit 04: Timeline of ADCs Exhibit 05: Key components Exhibit 06: Components of next-generation ADCs Exhibit 07: Advantages of ADCs Exhibit 08: Emergence of ADCs Exhibit 09: Marked ADCs products Exhibit 10: Pipeline portfolio of ADCs Exhibit 11: Pipeline share of ADCs Exhibit 12: Market share of ADCs in clinical development Exhibit 13: Few target antigens for ADCs in clinical development Exhibit 14: Top five companies share in ADC pipeline Exhibit 15: Global ADCs market 2015-2020 ($ billions) Exhibit 16: Five forces analysis Exhibit 17: Global ADCs market segmentation by MOA Exhibit 18: Components in IMGN technology Exhibit 19: Share of ADCs technologies Exhibit 20: Global ADCs market by geography 2015 Exhibit 21: ADCs market in Americas 2015 Exhibit 22: ADCs market in Europe 2015 Exhibit 23: ADCs market in Japan 2015 Exhibit 24: Global incidence of cancer 2015 and 2020 Exhibit 25: Impact of drivers Exhibit 26: Impact of drivers and challenges Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015 Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015 Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions) Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015 Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions) Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions) Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions) Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions) Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products Exhibit 36: F. Hoffmann La-Roche: Key takeaways Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions) Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs Exhibit 40: Seattle Genetics: ADC collaborations Exhibit 41: Seattle Genetics: Key takeaways Exhibit 42: Takeda: Business segmentation by revenue 2015 Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015 Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions) Exhibit 45: Takeda Pharmaceuticals: Key takeaways

F. Hoffmann-La Roche AG, Seattle Genetics Inc., Takeda Pharmaceutical Company, AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, Zymeworks.